Nexus Company Profile
What is the competitive landscape for NEXUS
NEXUS has twenty-four approved drugs.
There are five US patents protecting NEXUS drugs. There is one tentative approval on NEXUS drugs.
Summary for Nexus
| US Patents: | 5 |
| Tradenames: | 26 |
| Ingredients: | 23 |
| NDAs: | 24 |
| Patent Litigation for Nexus: | See patent lawsuits for Nexus |
| PTAB Cases with Nexus as petitioner: | See PTAB cases with Nexus as petitioner |
Drugs and US Patents for Nexus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexus | TRANEXAMIC ACID | tranexamic acid | SOLUTION;INTRAVENOUS | 216877-001 | Apr 16, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nexus | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-002 | Feb 28, 2023 | RX | Yes | Yes | 11,571,398 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nexus | FLUORESCEIN SODIUM | fluorescein sodium | INJECTABLE;INTRAVENOUS | 215709-002 | Sep 25, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Nexus | PROCAINAMIDE HYDROCHLORIDE | procainamide hydrochloride | INJECTABLE;INJECTION | 206332-002 | Oct 13, 2017 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nexus | ARSENIC TRIOXIDE | arsenic trioxide | INJECTABLE;INJECTION | 209780-001 | Nov 15, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nexus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2020232424 | ⤷ Start Trial |
| Australia | 2020276619 | ⤷ Start Trial |
| Japan | 2023091072 | ⤷ Start Trial |
| Japan | 2025071269 | ⤷ Start Trial |
| Japan | 2022532657 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nexus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2673237 | LUC00111 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326 |
| 2822954 | LUC00083 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
| 3347352 | 2290051-8 | Sweden | ⤷ Start Trial | PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REG. NO/DATE: EU/1/22/1671 20220819 |
| 2203431 | 92666 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
| 2666774 | 202040029 | Slovenia | ⤷ Start Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF SODIUM SALT; NATIONAL AUTHORISATION NUMBER: EU/1/19/1420; DATE OF NATIONAL AUTHORISATION: 20200213; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
